Related Experiment Video
Updated: Feb 9, 2026

Microscopic Cyst Resection for the Treatment of Patients Diagnosed with Epididymal Cyst
Published on: March 31, 2023
Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with
Ajai Chari1, Menaka Bhor2, Lamis Eldjerou2
1Mt Sinai Hospital, New York City, NY 10029, USA.
Aim:
To examine real-world treatment patterns in multiple myeloma (MM) patients treated with panobinostat.
Materials & Methods:
Using a US claims database, MM patients treated with panobinostat during 02/01/2015-01/31/2017 were evaluated. Lines of therapy, combination regimens, dosing and duration were measured.
Results:
Ninety-five patients were included (mean age: 61.4 years). Patients were heavily pretreated, with 88.4% exposed to both a proteasome inhibitor and an immunomodulatory agent. A panobinostat containing regimen was started in the fourth or more (86%) lines of therapy within a median of 3.77 years from initial treatment. The most common treatment combination was bortezomib/dexamethasone/panobinostat (31.6%) with 69.5% receiving the recommended dose (20 mg). Mean duration was 98.8 days.
Conclusion:
Patients received the recommended dose, most commonly with bortezomib and dexamethasone. Panobinostat was used in heavily pretreated patients within 4 years post-diagnosis, reflecting an advanced MM population.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
¹H NMR Signal Multiplicity: Splitting Patterns
Diagnosing Acidosis and Alkalosis
First, the pH level is assessed to determine whether the blood pH is normal (7.35–7.45), low (acidosis), or high (alkalosis).
Next, the PCO2 and...
Inhaled Medications
Multiple Allele Traits
Fixed Action Patterns
Patterns of Fever